Mode
Text Size
Log in / Sign up
Phase 3 N=56 Randomized Double-blind Treatment

Intra-Articular Injections of Platelet-Rich Plasma in Knee Osteoarthritis: Unique Application Versus Triple Application

Osteoarthritis

Enrolled (actual)
56
Serious AEs
0.0%
Results posted
Feb 2018
Primary outcome: Primary: Change in the Western Ontario and McMaster Universities (WOMAC) Ostearthritis Index (Therapeutic Effect) — 28.53; 22.27 units on a scale

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Platelet-Rich Plasma (Biological); rehabilitation exercises (Behavioral)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Universidad Autonoma de Nuevo Leon
Primary completion
Jul 2016

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in the Western Ontario and McMaster Universities (WOMAC) Ostearthritis Index (Therapeutic Effect)
28.53; 22.27
SECONDARY
Change in the SF-12 Health Survey (Quality of Life)
41.79; 44.74
SECONDARY
Change in the Visual Analog Scale (VAS) (Global Pain)
4.46; 3.26

Summary

The investigators include patients attending the outpatient clinic in the area of Orthopedics and Traumatology of the investigators hospital with a diagnosis of knee osteoarthritis, which treatment is medical. Patients will be divided into two groups. In both groups, they will be given verbal, clear and detailed information on the approach to follow, the intra-articular application of Platelet-Rich Plasma in the knee, plus rehabilitation exercises. In the first group will be held single application, while in the second group three applications will be made at an interval of two weeks each. Both groups will be assessed before and after application, together with outpatient follow-up by the SF-12 Health Survey (SF-12), Western Ontario and McMaster Universities Arthritis Index (WOMAC) and Visual Analogue Scale (VAS).

Eligibility Criteria

Inclusion Criteria

  • Age between 18 and 90 years
  • Patients with no previous treatment
  • Patients with Knee osteoarthritis grade 1-2 ( Kellgren-Lawrence based on radiographic findings)

Exclusion Criteria

  • Age 90 years
  • Patients with Knee osteoarthritis grade 3-4 ( Kellgren-Lawrence based on radiographic findings)
  • Patients with asociated Rheumatic syndromes
  • Patients with anticoagulant therapy
  • Patients with hepatic problems, Diabetes Mellitus, Coagulopathy, hearth conditions, immunodepressed, or infections
  • Pregnant patients
  • Patients with prosthetic or orthotic.
  • Patients with hemoglobin values < 11g/dl , platelets < 150,000/μL
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02370420). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search